Evidence map›Paper›PMID 31731753›Full record

ReviewCancers2019

Mouse Models for Immunotherapy in Hepatocellular Carcinoma.

Enya Li, Li Lin, Chia-Wei Chen, Da-Liang Ou

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Hepatocellular carcinoma biomarkers, an imminent need.World journal of gastrointestinal oncology · 2021
    Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Investigating T Cell Immunity in Cancer: Achievements and Prospects.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Enya LiGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Li LinGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Chia-Wei ChenGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.
Da-Liang OuGraduate Institute of Oncology, College of Medicine, National Taiwan University, Taipei 100, Taiwan.

Funding

Ministry of Science and Technology 106-2314-B-002-229-MY3Ministry of Science and Technology 107-2314-B-002 -210 -MY3Ministry of Science and Technology 107-3017-F-002-002Ministry of Science and Technology 108-2314-B-002 -075 -MY3Ministry of Science and Technology 108-3017-F-002-004National Taiwan University Hospital NTUH-107-S3837National Taiwan University Hospital NTUH-108-010NTU 107L9014NTU 108L901403YongLin Chair Grant S-01
6 · The paper itself

Abstract

Liver cancer is one of the dominant causes of cancer-related mortality, and the survival rate of liver cancer is among the lowest for all cancers. Immunotherapy for hepatocellular carcinoma (HCC) has yielded some encouraging results, but the percentage of patients responding to single-agent therapies remains low. Therefore, potential directions for improved immunotherapies include identifying new immune targets and checkpoints and customizing treatment procedures for individual patients. The development of combination therapies for HCC is also crucial and urgent and, thus, further studies are required. Mice have been utilized in immunotherapy research due to several advantages, for example, being low in cost, having high success rates for inducing tumor growth, and so on. Moreover, immune-competent mice are used in immunotherapy research to clarify the role that the immune system plays in cancer growth. In this review paper, the advantages and disadvantages of mouse models for immunotherapy, the equipment that are used for monitoring HCC, and the cell strains used for inducing HCC are reviewed.

Indexed as

hepatocellular carcinomaimmunotherapy

Identifiers

PMID31731753
PMCPMC6896030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.